NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

SUPN

$43.53

−$0.44 (−1.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SUPN with… →

SUPN Key Statistics

As of Sep 4, 2026
Trading
Open
$43.66
Previous Close
$43.97
Day's Range
43.43–44.11
52-Week Range
42.45–59.68
Volume
444.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.56
Valuation
Market Cap
$2.53B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.76
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.92
Financials (FY)
Revenue (FY)
$718.95M+8.63%
Net Income (FY)
−$38.55M−152.19%
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.23%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.13M
1-Year Return
−4.18%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
846.21K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SUPN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.41%
2025+37.44%
2024+24.95%
2023−18.87%
2022+22.33%
2021+15.90%
2020+6.07%
2019−28.60%
2018−16.64%
2017+57.82%
2016 (partial year)+8.84%

As of September 4, 2026.

SUPN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$718.95M−$38.55M−5.4%
2024$661.82M$73.87M11.2%
2023$607.52M$1.32M0.2%
2022$667.24M$60.71M9.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$718.95M$644.39M−$36.86M−$38.55M−5.4%
2024$661.82M$583.91M$75.56M$73.87M11.2%
2023$607.52M$523.74M$13.40M$1.32M0.2%
2022$667.24M$580.02M$45.61M$60.71M9.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SUPN Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricSUPNDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio3.052.3033% above
Profit margin−13.23%−3.14%10.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Supernus Pharmaceuticals, Inc. (SUPN) at $2.53B. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 778.

The most recent close on file for SUPN is $43.53, dated September 4, 2026. That is −$0.44 (−1.00%) against the previous close. Over the past 52 weeks the price has ranged from $42.45 to $59.68. The latest close sits 2.54% above that 52-week low.

Financial Health

In fiscal 2025, Supernus Pharmaceuticals, Inc. reported revenue of $718.95M. Against the prior fiscal year total of $661.82M, that is a change of +8.63%. The same year closed with a net loss of $38.55M. The reported profit margin is −13.23%. That is 10.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −1.92.

Across the 4 fiscal years on file, revenue moves from $667.24M in 2022 to $718.95M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 9.76. Measured against sales, the shares trade at 3.05 times revenue. On price-to-sales that is 32.78% above the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.56. Annualized volatility over the trailing 10 years is 43.81%. The trailing one-year price return is −4.18%. Across 10 years the annualized return works out at +7.08%.

Growth & Income

The record shows no dividend for SUPN.

The strongest complete calendar year on file is 2017 at +57.82%; the weakest is 2019 at −28.60%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the price is −12.41%.

Peer Comparison

Supernus Pharmaceuticals, Inc. (SUPN) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Supernus Pharmaceuticals, Inc. SUPN $2.53B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Supernus Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Visit website →